Concepedia

Neal David

ND

Statistics

Publications

4

Citations

907

H-Index

4

Active since

2008

Affiliations

Bristol-Myers Squibb (United States)(Current)

Brooklyn Chest Hospital

Délégation Paris 7

Université Paris Cité

Hôpital Saint-Louis

Neal David is an author at Bristol-Myers Squibb (United States) specializing in pharmacovigilance, human immunodeficiency virus pharmacotherapy, and highly active antiretroviral therapy.

Publications per year

2008–2010

4

Publications

4

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría et al. · The Lancet · 2008 · 482 citations

, , +16

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 255 citations

, , +17

Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients

Daniel R Malan, Edrich Krantz, Neal David et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2008 · 150 citations

, , +17

96-Week Efficacy and Safety of Atazanavir, With and Without Ritonavir, in a HAART Regimen in Treatment-Naive Patients

Daniel R Malan, Edrich Krantz, Neal David et al. · Journal of the International Association of Physicians in AIDS Care · 2010 · 20 citations

, , +17

1–4 of 4